SCHEMBL20530026

SCHEMBL20530026

O=C(CCCc1ccc(I)cc1)NCCCC[C@H](NC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ ALB P02768 12/20 0.53
▸ CA9 Q16790 1/20 0.48
▸ KMT2A Q03164 1/20 0.47
▸ MDM2 Q00987 1/20 0.46
▸ TLR2 O60603 2/20 0.44
▸ FOLH1 Q04609 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31298671 0.94 ALB (0.48) ALBCA9KMT2AMDM2TLR2
SCHEMBL31298693 0.92 ALB (0.48) ALBCA9TLR2
SCHEMBL29521888 0.91 ALB (0.44) ALBCA9KMT2AMDM2TLR2
SCHEMBL20530037 0.90 ALB (0.47) ALBCA9MDM2TLR2
SCHEMBL31298675 0.90 ALB (0.47) ALBCA9MDM2TLR2
SCHEMBL30905431 0.90 ALB (0.53) ALBCA9KMT2AMDM2TLR2
SCHEMBL31758278 0.89 ALB (0.62) ALBCA9KMT2AMDM2TLR2
SCHEMBL30895420 0.87 KMT2A (0.52) KMT2AMDM2TLR2FOLH1
SCHEMBL20530074 0.86 FOLH1 (0.55) KMT2ATLR2FOLH1
SCHEMBL31298701 0.86 CPB1 (0.45) ALBKMT2ATLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240050599-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES CORNELL UNIVERSITY (US) 2024-02-15 — — US disclosed
US-20230285603-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES CORNELL UNIVERSITY (US) 2023-09-14 — — US disclosed
US-20230114130-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES COMELL UNIVERSITY (US) 2023-04-13 — — US disclosed
US-20210128757-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLEPHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES CORNELL UNIVERSITY (US) 2021-05-06 — — US disclosed
US-20210121584-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES CORNELL UNIVERSITY (US) 2021-04-29 — — US disclosed
US-20200405888-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES CORNELL UNIVERSITY (US) 2020-12-31 — — US disclosed
US-10806806-B2 Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies CORNELL UNIVERSITY (US) 2020-10-20 — — US disclosed
EP-3609541-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES Cornell University (US) 2020-02-19 — — EP disclosed
US-20190015531-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES CORNELL UNIVERSITY 2019-01-17 — — US disclosed
WO-2018187631-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES CORNELL UNIVERSITY (US) 2018-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210121584-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES VHL, GLS, GPER1 ALB 2495/4885CA9 379/4885KMT2A 3904/4885
US-20210128757-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLEPHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES MC2R, OGFR, GLS ALB 3175/4885CA9 365/4885KMT2A 4100/4885
US-20230114130-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES VHL, GLS, KRAS ALB 2124/4885CA9 105/4885KMT2A 3901/4885
US-20230285603-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES VHL, GLS, GPER1 ALB 2495/4885CA9 379/4885KMT2A 3904/4885
US-20240050599-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES VHL, GLS, GPER1 ALB 2495/4885CA9 379/4885KMT2A 3904/4885
US-20200405888-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES VHL, GLS, GPER1 ALB 2495/4885CA9 379/4885KMT2A 3904/4885
US-10806806-B2 Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies VHL, GLS, GPER1 ALB 2495/4885CA9 379/4885KMT2A 3904/4885
US-20190015531-A1 TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES VHL, GLS, GPER1 ALB 2495/4885CA9 379/4885KMT2A 3904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback